Table 1.

Characteristics of the total patient sample (N = 149 262 [n = 65 620 men; n = 83 642 women]): A) Primary prevention group; B) secondary prevention group.

A) CHARACTERISTICSPRIMARY PREVENTION GROUP*
TOTAL NO. OF PATIENTS (N = 139 025), N (%)MALE (N = 60 013), N (%)FEMALE (N = 79 012), N (%)
Taking statins5955 (4)3111 (5)2844 (4)
Not taking statins133 070 (96)56 902 (95)76 168 (96)
Age ≥ 75 y14 814 (11)6120 (10)8694 (11)
Taking statins and aged ≥ 75 y1374 (1)577 (1)797 (1)
Lipid testing in past 5 y32 950 (24)14 155 (24)18 435 (23)
Lipid testing inside age ranges23 736 (17)10 461 (17)13 275 (17)
Lipid testing and ≥ 75 y3528 (3)1299 (2)2229 (3)
Lipid testing while taking statins1596 (1)813 (1)756 (0)
B) CHARACTERISTICSSECONDARY PREVENTION GROUP*
TOTAL NO. OF PATIENTS (N = 10 237), N (%)MALE (N = 5607), N (%)FEMALE (N = 4630), N (%)
Taking statins3013 (29)1832 (32)1181 (26)
Not taking statins7224 (71)3775 (67)3449 (75)
Age ≥ 75 y5374 (52)2547 (45)2827 (61)
Taking statins and aged ≥ 75 y1472 (14)775 (14)697 (15)
Lipid testing in past 5 y4387 (43)2534 (45)1853 (40)
Lipid testing inside age ranges2288 (22)1477 (26)811 (18)
Lipid testing and aged ≥ 75 y2069 (20)1041 (19)1028 (22)
Lipid testing while taking statins911 (9)561 (10)350 (7)
  • * The 2016 Canadian Cardiovascular Society guidelines3 were followed for age cutoffs.